Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-world Effectiveness and Safety in HR+/HER2- Advanced or Metastatic BC Patients Treated With Ribociclib or Alpelisib: A European Non-interventional Retrospective Study (REASSURE)

NCT06705504 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT06705504
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06705504 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-world Effectiveness and Safety in HR+/HER2- Advanced or Metastatic BC Patients Treated With Ribociclib or Alpelisib: A European Non-interventional Retrospective Study (REASSURE)
Lead sponsor
Novartis
Phase
Observational
Overall status
Completed
Start date
June 11, 2021
Completion date
November 30, 2023
Enrollment
435 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hormone receptor positive her-2 negative breast cancer